Please ensure Javascript is enabled for purposes of website accessibility

Why Diplomat Pharmacy Sank Today

By Brian Orelli, PhD - Updated Feb 27, 2018 at 2:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors fret after the company reports fourth-quarter results.

What happened

Diplomat Pharmacy (DPLO) shares are down 8.6% at 3:03 p.m. EST Tuesday, having been down as much as 12.8%, after the company announced fourth-quarter earnings after the bell yesterday.

The results shouldn't have been much of a shock to investors -- the company said in January that 2017 revenue would be at the midpoint of its previously announced guidance of $4.4 billion to $4.6 billion, and adjusted EBITDA would be at the upper end of the expected range of $99 million and $102 million.

The official full-year revenue came in at $4.485 billion while EBITDA was $101.8 million; these figures appear pretty close to the updated guidance.

Woman in lab coat looking at medications in a drawer

Image source: Getty Images.

So what

Investors are likely continuing to fret over Diplomat Pharmacy's move into the pharmacy benefit management (PBM) business with the acquisitions of LDI Integrated Pharmacy Services and National Pharmaceutical Services.

Management guided for 2018 adjusted earnings of $0.87 to $0.97 per share, which is 9.5% higher at the midpoint than the $0.84 per share Diplomat Pharmacy posted in 2017. But the company has to show that it can hit the midrange or higher. The bottom of the range doesn't provide much growth.

Investors could also be worried about how the company will fare after co-founder and CEO Phil Hagerman retired abruptly in January. Jeff Park, who was a board member, took over as interim CEO while the board looks for a permanent replacement.

Now what

After today's move, shares of Diplomat sit about where they were in January before the preliminary fourth-quarter results were announced, but substantially higher than where they were after the initial announcement that the company was jumping feet first into the PBM business. This suggests investors are having trouble valuing the transition. If Diplomat can prove that it made a smart move by hitting its 2018 guidance and accelerating into 2019, investors willing to take on the unknown-valuation risk should be rewarded.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Diplomat Pharmacy, Inc. Stock Quote
Diplomat Pharmacy, Inc.
DPLO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.